Abstract:Glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), two members of class B1 G protein-coupled receptors, play important roles in glucose homeostasis and energy metabolism. They share a high degree of sequence homology but have different functionalities. Unimolecular dual agonists of both receptors developed recently displayed better clinical efficacies than that of monotherapy. To study the underlying molecular mechanisms, we determined high-resolution cryo-electron microscopy structures of GLP-1R or GCGR in complex with heterotrimeric Gs protein and three GLP-1R/GCGR dual agonists including peptide 15, MEDI0382 (cotadutide) and SAR425899 with variable activating profiles at GLP-1R versus GCGR. Compared with related structures reported previously and supported by our published pharmacological data, key residues responsible for ligand recognition and dual agonism were identified. Analyses of peptide conformational features revealed a difference in side chain orientations within the first three residues, indicating that distinct engagements in the deep binding pocket are required to achieve receptor selectivity. The middle region recognizes extracellular loop 1 (ECL1), ECL2, and the top of transmembrane helix 1 (TM1) resulting in specific conformational changes of both ligand and receptor, especially the dual agonists reshaped ECL1 conformation of GLP-1R relative to that of GCGR, suggesting an important role of ECL1 interaction in executing dual agonism. Structural investigation of lipid modification showed a better interaction between lipid moiety of MEDI0382 and TM1-TM2 cleft, in line with its increased potency at GCGR than SAR425899. Together, the results provide insightful information for the design and development of improved therapeutics targeting these two receptors simultaneously.

Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Molecular basis of enhanced GLP-1 signaling mediated by GLP-1(9-36) in conjunction with LSN3318839

Allosteric Modulators Enhancing GLP-1 Binding to GLP-1R via a Transmembrane Site

Discovery of Novel Allosteric Modulators Targeting an Extra-Helical Binding Site of GLP-1R Using Structure- and Ligand-Based Virtual Screening

Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein

A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor

Structural Basis of Orientated Asymmetry in a Mglu Heterodimer

Conformational Dynamics of the Activated GLP-1 Receptor-Gs Complex Revealed by Cross-Linking Mass Spectrometry and Integrative Structure Modeling.

Full-length human GLP-1 receptor structure without orthosteric ligands

Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with G s proteins

Conformational Dynamics of the Activated GLP-1 Receptor-G s Complex Revealed by Cross-Linking Mass Spectrometry and Integrative Structure Modeling

Delineating the activation mechanism and conformational landscape of a class B G protein-coupled receptor glucagon receptor

Delineating the stepwise millisecond allosteric activation mechanism of the class C GPCR dimer mGlu5

Structural basis of positive allosteric modulation of metabotropic glutamate receptor activation and internalization

Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation

Mechanism of Β 2 AR Regulation by an Intracellular Positive Allosteric Modulator

Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs

Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface

Structural Analysis of the Dual Agonism at GLP-1R and GCGR